Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589949 | 0.94 | PRKCA (0.40) | PRKCAMMP12CNR2PTGER4KDM4E | |
| SCHEMBL3091875 | 0.91 | PRKCA (0.40) | PRKCAMMP12CNR2KDM4EHPGD | |
| SCHEMBL27713477 | 0.91 | PRKCA (0.40) | PRKCAMMP12CNR2KDM4EHPGD | |
| SCHEMBL3589660 | 0.89 | PRKCA (0.39) | PRKCAMMP12CNR2KDM4EHPGD | |
| SCHEMBL3596844 | 0.89 | PRKCA (0.39) | PRKCAMMP12CNR2KDM4EHPGD | |
| SCHEMBL3362749 | 0.89 | PRKCA (0.39) | PRKCAMMP12CNR2PTGER4KDM4E | |
| SCHEMBL3584923 | 0.89 | PTGER4 (0.40) | PRKCAMMP12CNR2PTGER4KDM4E | |
| SCHEMBL4821691 | 0.88 | CNR2 (0.41) | PRKCAMMP12CNR2KDM4EHPGD | |
| SCHEMBL4821680 | 0.88 | CNR2 (0.40) | PRKCAMMP12CNR2PTGER4KDM4E | |
| SCHEMBL13939958 | 0.88 | CNR2 (0.40) | PRKCAMMP12CNR2PTGER4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662809-B2 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2010-02-16 | — | — | US | disclosed |
| US-20080261938-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-23 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1807397-A2 | TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2007-07-18 | — | — | EP | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| WO-2006046039-A2 | TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2006-05-04 | — | — | WO | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261938-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, HAVCR2 | PRKCA 4232/4885MMP12 2495/4885CNR2 388/4885 |
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | PRKCA 3479/4885MMP12 3512/4885CNR2 1457/4885 |
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | PRKCA 3479/4885MMP12 3512/4885CNR2 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.